Reinduction of Bevacizumab with Pegylated Liposomal Doxorubicin in Recurrent Glioblastoma
Author Information
Author(s): Almubarak Mohammed, Newton Michael, Altaha Ramin
Primary Institution: Mary Babb Randolph Cancer Center, West Virginia University Hospital
Hypothesis
Replacing irinotecan with another cytotoxic chemotherapy agent may overcome the resistance to the BI regimen.
Conclusion
Reinducing the patient with bevacizumab and pegylated liposomal doxorubicin showed significant antitumor activity.
Supporting Evidence
- Bevacizumab has shown promising results in treating recurrent glioblastoma.
- The patient had a significant partial response to bevacizumab with irinotecan before progression.
- Reinduction with pegylated liposomal doxorubicin led to substantial decrease in tumor size.
Takeaway
A patient with brain cancer had a good response to a new treatment combining two drugs after previous treatments stopped working.
Methodology
The patient was treated with various chemotherapy regimens, including reinduction with bevacizumab and pegylated liposomal doxorubicin.
Limitations
The patient declined further chemotherapy and imaging after initial improvement.
Participant Demographics
A 56-year-old male patient with recurrent glioblastoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website